48,975
edits
Difference between revisions of "Epithelioid hemangioendothelioma"
Jump to navigation
Jump to search
Epithelioid hemangioendothelioma (view source)
Revision as of 14:31, 5 April 2024
, 14:31, 5 April 2024no edit summary
| (9 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
| Micro = large epithelioid perivascular cells with abundant pale eosinophilic cytoplasm and cytoplasmic vacuolation ("blister cells") - may form lumen and have RBC within, vesicular nucleus +/-prominent nucleolus; tuft-like projections into capillaries; cells may be in well-circumscribed paucicellular nodules ''or'' poorly formed cellular aggregates | | Micro = large epithelioid perivascular cells with abundant pale eosinophilic cytoplasm and cytoplasmic vacuolation ("blister cells") - may form lumen and have RBC within, vesicular nucleus +/-prominent nucleolus; tuft-like projections into capillaries; cells may be in well-circumscribed paucicellular nodules ''or'' poorly formed cellular aggregates | ||
| Subtypes = | | Subtypes = | ||
| LMDDx = epithelioid [[angiosarcoma]], [[hemangioma]] | | LMDDx = epithelioid [[angiosarcoma]], [[hemangioma]], [[epithelioid sarcoma]] | ||
| Stains = | | Stains = | ||
| IHC = CD31 +ve, CD34 +ve, factor VIII +ve | | IHC = CD31 +ve, CD34 +ve, factor VIII +ve, CAMTA1 +ve, TFE3 +ve/-ve | ||
| EM = | | EM = | ||
| Molecular = | | Molecular = gene fusions: WWTR1-CAMTA1 (approximately 90% of cases), YAP1-TFE3 (small number of cases) | ||
| IF = | | IF = | ||
| Gross = | | Gross = | ||
| Grossing = | | Grossing = | ||
| Site = [[soft tissue lesions|soft tissue]] - see ''[[vascular tumours]]'' | | Site = [[soft tissue lesions|soft tissue]] - see ''[[vascular tumours]]'', classically [[liver]] - but various sites reported | ||
| Assdx = | | Assdx = | ||
| Syndromes = | | Syndromes = | ||
| Line 37: | Line 37: | ||
*Malignant.<ref name=Ref_WMSP603>{{Ref WMSP|603}}</ref> | *Malignant.<ref name=Ref_WMSP603>{{Ref WMSP|603}}</ref> | ||
*Adults - wide age range. | *Adults - wide age range. | ||
*Associated with oral contraceptives, vinyl chloride.<ref name=pmid20165548/> | *Associated with [[oral contraceptives]], vinyl chloride.<ref name=pmid20165548/> | ||
*Rare.<ref name=pmid23589078/> | *Rare.<ref name=pmid23589078/> | ||
| Line 43: | Line 43: | ||
*Excision<ref name=pmid8941001/> if feasible. | *Excision<ref name=pmid8941001/> if feasible. | ||
*Chemotherapy - not standardized.<ref name=pmid23589078>{{Cite journal | last1 = Chevreau | first1 = C. | last2 = Le Cesne | first2 = A. | last3 = Ray-Coquard | first3 = I. | last4 = Italiano | first4 = A. | last5 = Cioffi | first5 = A. | last6 = Isambert | first6 = N. | last7 = Robin | first7 = YM. | last8 = Fournier | first8 = C. | last9 = Clisant | first9 = S. | title = Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). | journal = Cancer | volume = 119 | issue = 14 | pages = 2639-44 | month = Jul | year = 2013 | doi = 10.1002/cncr.28109 | PMID = 23589078 }}</ref> | *Chemotherapy - not standardized.<ref name=pmid23589078>{{Cite journal | last1 = Chevreau | first1 = C. | last2 = Le Cesne | first2 = A. | last3 = Ray-Coquard | first3 = I. | last4 = Italiano | first4 = A. | last5 = Cioffi | first5 = A. | last6 = Isambert | first6 = N. | last7 = Robin | first7 = YM. | last8 = Fournier | first8 = C. | last9 = Clisant | first9 = S. | title = Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). | journal = Cancer | volume = 119 | issue = 14 | pages = 2639-44 | month = Jul | year = 2013 | doi = 10.1002/cncr.28109 | PMID = 23589078 }}</ref> | ||
*[[Liver transplantation]].<ref>{{Cite journal | last1 = Nudo | first1 = CG. | last2 = Yoshida | first2 = EM. | last3 = Bain | first3 = VG. | last4 = Marleau | first4 = D. | last5 = Wong | first5 = P. | last6 = Marotta | first6 = PJ. | last7 = Renner | first7 = E. | last8 = Watt | first8 = KD. | last9 = Deschênes | first9 = M. | title = Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. | journal = Can J Gastroenterol | volume = 22 | issue = 10 | pages = 821-4 | month = Oct | year = 2008 | doi = | PMID = 18925305 }}</ref> | |||
Prognosis - liver: | Prognosis - liver: | ||
*~55% five-year survival.<ref name=pmid8941001>{{Cite journal | last1 = Läuffer | first1 = JM. | last2 = Zimmermann | first2 = A. | last3 = Krähenbühl | first3 = L. | last4 = Triller | first4 = J. | last5 = Baer | first5 = HU. | title = Epithelioid hemangioendothelioma of the liver. A rare hepatic tumor. | journal = Cancer | volume = 78 | issue = 11 | pages = 2318-27 | month = Dec | year = 1996 | doi = | PMID = 8941001 }}</ref> | *~55% five-year survival.<ref name=pmid8941001>{{Cite journal | last1 = Läuffer | first1 = JM. | last2 = Zimmermann | first2 = A. | last3 = Krähenbühl | first3 = L. | last4 = Triller | first4 = J. | last5 = Baer | first5 = HU. | title = Epithelioid hemangioendothelioma of the liver. A rare hepatic tumor. | journal = Cancer | volume = 78 | issue = 11 | pages = 2318-27 | month = Dec | year = 1996 | doi = | PMID = 8941001 }}</ref> | ||
**Better than other liver tumours. | **Better than other [[liver tumours]]. | ||
==Gross== | ==Gross== | ||
* | *Classically, a [[liver]] lesion - but found elsewhere.<ref>{{Cite journal | last1 = Cardinal | first1 = J. | last2 = de Vera | first2 = ME. | last3 = Marsh | first3 = JW. | last4 = Steel | first4 = JL. | last5 = Geller | first5 = DA. | last6 = Fontes | first6 = P. | last7 = Nalesnik | first7 = M. | last8 = Gamblin | first8 = TC. | title = Treatment of hepatic epithelioid hemangioendothelioma: a single-institution experience with 25 cases. | journal = Arch Surg | volume = 144 | issue = 11 | pages = 1035-9 | month = Nov | year = 2009 | doi = 10.1001/archsurg.2009.121 | PMID = 19917940 }}</ref><ref name=pmid37541086>{{cite journal |authors=Haughey AM, Moloney BM, O'Brien CM |title=Epithelioid Haemangioendothelioma; Not simply a hepatic pathology |journal=Clin Imaging |volume=102 |issue= |pages=42–52 |date=October 2023 |pmid=37541086 |doi=10.1016/j.clinimag.2023.07.003 |url=}}</ref> | ||
*Case reports of EHE in a wide number of anatomical sites (bowel,<ref name=pmid30238810>{{cite journal |authors=Spasic S, Brcic I, Freire R, Garcia-Buitrago MT, Rosenberg AE |title=Epithelioid Hemangioendothelioma of the Bowel in Crohn's Disease: The First Reported Case |journal=Int J Surg Pathol |volume=27 |issue=4 |pages=423–426 |date=June 2019 |pmid=30238810 |doi=10.1177/1066896918801527 |url=}}</ref>, parotid<ref name=pmid31530411>{{cite journal |authors=Suarez-Zamora DA, Rodriguez-Urrego PA, Hakim-Tawil JA, Palau-Lazaro MA |title=Epithelioid hemangioendothelioma of the parotid gland: A case report in an unusual location with a review of the literature |journal=Rev Esp Patol |volume=52 |issue=4 |pages=260–264 |date=2019 |pmid=31530411 |doi=10.1016/j.patol.2019.04.002 |url=}}</ref> mediastinum<ref>{{cite journal |authors=Kim SH, Kim YS, Jang MH, Kwon HJ |title=Mediastinal Epithelioid Hemangioendothelioma Invading Superior Vena Cava: A Case Report and Review of Literature |journal=Curr Med Imaging Rev |volume=15 |issue=3 |pages=349–352 |date=2019 |pmid=31989887 |doi=10.2174/1573405614666180124141817 |url=}}</ref>). | |||
==Microscopic== | ==Microscopic== | ||
| Line 66: | Line 68: | ||
*[[Cholangiocarcinoma]]. | *[[Cholangiocarcinoma]]. | ||
*[[Fibrolamellar hepatocellular carcinoma]]. | *[[Fibrolamellar hepatocellular carcinoma]]. | ||
*[[Epithelioid sarcoma]].<ref name=pmid26414223/> | |||
===Images=== | ===Images=== | ||
| Line 81: | Line 84: | ||
*CD34 +ve. | *CD34 +ve. | ||
*Factor VIII +ve. | *Factor VIII +ve. | ||
*CAMTA1 +ve.<ref name=pmid26414223>{{cite journal |authors=Doyle LA, Fletcher CD, Hornick JL |title=Nuclear Expression of CAMTA1 Distinguishes Epithelioid Hemangioendothelioma From Histologic Mimics |journal=Am J Surg Pathol |volume=40 |issue=1 |pages=94–102 |date=January 2016 |pmid=26414223 |doi=10.1097/PAS.0000000000000511 |url=}}</ref> | |||
*TFE3 +ve - minority of cases. | |||
==Molecular== | |||
Gene fusions:<ref name=pmid26414223/> | |||
*WWTR1-CAMTA1 - seen in approximately 90% of cases. | |||
*YAP1-TFE3 fusion gene - <5% of cases. | |||
==See also== | ==See also== | ||
*[[Vascular tumours]]. | *[[Vascular tumours]]. | ||
*[[Kaposiform hemangioendothelioma]]. | |||
*[[Hemangioendothelioma]]. | |||
*[[Liver hemangioma]]. | |||
==References== | ==References== | ||